# ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

> **NCT02029443** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 306 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Richter's Syndrome
- Prolymphocytic Leukemia

## Interventions

- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT02029443
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-01-30
- **Primary completion:** 2021-07-15
- **Final completion:** 2027-06-09
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029443, "ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT02029443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*